Table 3.
Factors associated with 12-month virological success (<500 copies/mL) in the 106 HIV-1-infected children randomised in the ANRS 12206 MONOD study (Abidjan and Ouagadougou, February 2013–February 2015)
| Total N = 106 | Virological success (<500 copies/mL) N = 89 | Virological failure (≥500 copies/mL) N = 17 | p value | |
|---|---|---|---|---|
| Country | 0.83 | |||
| Abidjan | 71 (67.0) | 60 (67.4) | 11 (64.7) | |
| Ouagadougou | 35 (33.0) | 29 (32.6) | 6 (35.3) | |
| Sex | 0.81 | |||
| Female | 59 (55.7) | 50 (56.2) | 9 (52.9) | |
| Male | 47 (44.3) | 39 (43.8) | 8 (47.1) | |
| Treatment arm | 0.73 | |||
| AZT/ABC + 3TC + LPV/r | 54 (50.9) | 46 (51.7) | 8 (47.1) | |
| ABC + 3TC + EFV | 52 (49.1) | 43 (48.3) | 9 (52.9) | |
| Main caregiver for children | 1.00 | |||
| Mother main caregiver | 88 (83.0) | 74 (83.2) | 14 (82.4) | |
| Father/other in charge of care | 18 (17.0) | 15 (16.8) | 3 (17.6) | |
| Father informed of the child’s HIV status | 0.30 | |||
| No | 44 (41.5) | 35 (39.3) | 9 (52.9) | |
| Yes | 62 (58.5) | 54 (60.7) | 8 (47.1) | |
| History of antiretroviral drug exposure | 0.63 | |||
| Prenatal maternal ART | 9 (8.5) | 7 (7.9) | 2 (11.8) | |
| PMTCT only | 32 (30.2) | 27 (30.3) | 5 (29.4) | |
| Postnatal maternal ART only | 13 (12.3) | 12 (13.5) | 1 (5.9) | |
| PMTCT and postnatal maternal ART | 10 (9.4) | 7 (7.9) | 3 (17.6) | |
| No previous exposure to any PMTCT or ART | 42 (39.6) | 36 (40.4) | 6 (35.3) | |
| Age at randomisation | 0.39 | |||
| <24 months | 41 (38.7) | 36 (40.4) | 5 (29.4) | |
| ≥24 months | 65 (61.3) | 53 (59.6) | 12 (70.6) | |
| WHO clinical stage at randomisation | ||||
| Stage 1, 2, 3 | 83 (78.3) | 73 (82.0) | 10 (58.8) | 0.05 |
| Stage 4 | 23 (21.7) | 16 (18.0) | 7 (41.2) | |
| Z-score Weight-for-age at ART initiation | 0.35 | |||
| Normal | 50 (47.2) | 44 (49.4) | 6 (35.3) | |
| Moderate | 22 (20.7) | 19 (21.4) | 3 (17.6) | |
| Severe | 34 (32.1) | 26 (29.2) | 8 (47.1) | |
| Z-score Height-for-age at ART initiation | 0.09 | |||
| Normal | 55 (51.9) | 50 (56.2) | 5 (29.4) | |
| Moderate | 21 (19.8) | 15 (16.8) | 6 (35.3) | |
| Severe | 30 (28.3) | 24 (27.0) | 6 (35.3) | |
| CD4 % at ART initiation | 0.60 | |||
| >35% | 13 (12.3) | 10 (11.2) | 3 (17.6) | |
| 25–35% | 19 (17.9) | 17 (19.1) | 2 (11.8) | |
| <25% or missing | 74 (69.8) | 62 (69.7) | 12 (70.6) |
Data are presented as n (%)
AZT Zidovudine, 3TC Lamivudine, ABC Abacavir, EFV Efavirenz, LPV/r Lopinavir-boosted ritonavir, ART Antiretroviral therapy, PMTCT Prevention of mother-to-child-transmission, WHO World Health Organization. Normal: Z-score ≥ 2 Standard Deviations (SD); Z-score <-2 SD corresponds to moderate malnutrition, being severe form at a Z-score<-3 SD